ALZHEIMERS

Objectives

  • Recall the concept of cognition.

  • Review pathophysiology of Alzheimer’s disease.

  • Discuss the progression and stages of Alzheimer’s disease.

  • Discuss the complications of Alzheimer’s disease.

  • Explain the comprehensive assessment for a client suffering from Alzheimer’s disease.

  • Interpret the expected assessment findings for a client suffering from Alzheimer’s disease to determine actual and potential consequences.

  • Identify client goals and determine expected outcomes for a client suffering from Alzheimer’s disease.

  • Describe nursing and collaborative interventions required to treat and monitor a client suffering from Alzheimer’s disease.

  • Identify pharmacological therapy used to treat Alzheimer’s disease and associated considerations.

  • Identify family and caregiver challenges and education priorities.

Alzheimer’s Disease Overview

    Alzheimer’s deals with cognition. It affects the short-term memory first.

  • Definition: Alzheimer’s Disease (AD) is a degenerative neurologic disorder affecting memory, thinking, and behavior.

  • Nickname: Often referred to as “The Long Good-bye.”

  • Cure Status: Currently, there is no cure for Alzheimer's Disease.

Pathophysiology of Alzheimer’s Disease

  • Type of Dementia: AD is the most common type of dementia.

  • Microscopic Changes: Characterized by neurofibrillary tangles, neuritic plaques, and beta amyloid deposits.

  • Neurotransmitter Abnormalities: Significant changes in neurotransmitter levels are observed in Alzheimer's patients.

Incidence and Prevalence

  • Incidence increases with age, particularly after the age of 65.

  • Alzheimer’s Disease can affect individuals older than 40 years.

  • In the U.S., approximately 5.7 million individuals over 65 are affected.

Comparison of Brain Structures

  • A comparison of brain slices illustrates changes due to Alzheimer's Disease:

    • The Alzheimer's brain is markedly smaller than a healthy brain.

    • There is observable atrophy in the folds and grooves of the cerebral cortex, and the ventricles are enlarged.

    • The hippocampus is responsible for memory

    • Alzheimer’s can only be diagnosed when a brain biopsy is done; however, the diagnosis is more commonly based on clinical evaluations, cognitive testing, and neuroimaging studies that can reveal characteristic changes associated with the disease.

Etiology and Genetic Risk Factors

  • Risk Factors:

    • Age: Higher risk as age increases.

    • Gender: Variations in gender impact risk.

    • Genetics: Family history may increase risk; however, the exact cause of Alzheimer's Disease remains unknown.

Stages of Alzheimer’s Disease

Stage I: Mild Cognitive Impairment

  • Client may be disoriented but capable of handling many daily activities.

Stage II: Moderate (2-3 Years)

  • Cognitive Impairments:

    • Impairment of all cognitive functions.

    • Difficulty handling finances and possible depression/agitation.

    • Increasing dependency on activities of daily living (ADLs).

    • Visuospatial deficits and difficulties in speech and language.

    • Possible incontinence and psychotic behaviors such as delusions.

    • Episodes of wandering may occur, alongside sleep disturbances.

Stage III: Severe (Bedridden)\n- Completely Incapacitated:

  • Total dependency in ADLs.

  • Loss of mobility and verbal communication skills.

  • Possible seizures and tremors, along with agnosia (inability to process sensory information).

Health Promotion and Maintenance

  • Prevention: No definitive method to prevent AD exists. Chronic health issues can exacerbate symptoms.

  • Lifestyle Modifications:

    • Emphasizing the importance of a balanced diet and regular exercise.

    • Advising against smoking and excessive alcohol intake.

Comprehensive Assessment

Recognizing Cues

History

  • Gather information about:

    • Onset, duration, and progression of symptoms.

    • Functional status and any significant changes in behavior.

Physical Assessment

  • Evaluate cognitive functions such as attention, concentration, judgment, perception, learning memory, and communication.

Psychosocial Assessment

  • Obtain information about the individual's social and emotional well-being.

Laboratory and Imaging Assessment

  • Utilize CT scans, MRIs, and genetic testing;

  • Autopsy: Brain tissue examination is the only definitive diagnosis.

Analysis of Alzheimer's Disease

Analyze Cues & Prioritize Hypotheses

  • Identify hypotheses such as:

    • Decreased memory and cognition due to neuronal changes in the brain.

    • Potential for injury or falls due to wandering or inability to remain mobile independently.

    • Potential for elder abuse due to the patient’s requirements for increased care as the disease progresses.

Planning and Implementation

Generate Solutions and Take Action

  • Focus on managing:

    • Memory and cognitive dysfunction.

    • Preventing injuries or falls.

    • Preventing elder abuse.

Cognitive and Nonpharmacologic Interventions

  • Cognitive Stimulation: Provide activities that engage cognitive abilities such as puzzles and memory games.

  • Environmental Structuring: Modify surroundings to enhance safety & ease of navigation.

  • Therapies: Orientation or validation therapy to encourage patient engagement in their reality.

  • Self-Management Promotion: Encourage independence in possible areas.

  • Continence Promotion: Address bowel and bladder control.

  • Communication Support: Utilize strategies to enhance patient communication.

Care Coordination and Transition Management

  • Home Care Management: Formulate plans for in-home care.

  • Respite Care: Options for caregiver relief.

  • Education: Instruct families on behavior management and drug therapy. Maintain mobility as long as possible.

Pharmacological Treatments

  • Current research indicates no drugs actually slow the progression of Alzheimer’s Disease but some may improve symptoms:

    • Cholinesterase Inhibitors: Examples include Donepezil (Aricept), Galantamine (Razadyne), and Rivastigmine (Exelon).

    • Memantine (Namenda): NMDA receptor antagonist.

    • Vitamin E: Used for cognitive health.

    • SSRIs for depression: Such as Paroxetine (Paxil) and Sertraline (Zoloft).

    • Psychotropic Drugs: To manage symptoms of agitation, aggression, and psychosis: includes Aripiprazole (Abilify), Clozapine (Clozaril), Haloperidol (Haldol), among others.

Evaluation: Outcomes

  • Evaluate effectiveness through:

    • Maintenance of cognitive functions and memory.

    • Injury prevention measures.

    • Management of caregiver stress to mitigate the risk of elder abuse.

Objectives

  1. Recall the concept of cognition.

    • Cognition encompasses mental functions such as attention, concentration, judgment, perception, learning memory, and communication, which are evaluated during assessment.

  2. Review pathophysiology of Alzheimer’s disease.

    • Alzheimer’s Disease (AD) is the most common type of dementia, characterized by microscopic changes including neurofibrillary tangles, neuritic plaques, and beta amyloid deposits. Significant changes in neurotransmitter levels are also observed.

  3. Discuss the progression and stages of Alzheimer’s disease.

    • Stage I: Mild Cognitive Impairment: Client may be disoriented but capable of handling many daily activities.

    • Stage II: Moderate (2-3 Years): Impairment of all cognitive functions, difficulty with finances, increasing dependency in ADLs, visuospatial deficits, speech/language difficulties, possible incontinence and psychotic behaviors (delusions), wandering, and sleep disturbances.

    • Stage III: Severe (Bedridden): Total dependency in ADLs, loss of mobility and verbal communication, possible seizures and tremors, along with agnosia.

  4. Discuss the complications of Alzheimer’s disease.

    • potential for injury or falls (due to wandering or impaired mobility)

    • potential for elder abuse (due to increased care requirements)

    • seizures

    • tremors

    • agnosia (prevents a person from recognizing objects, people, or sounds using one or more senses)

FASTA ACRONYM: FALLS, ABUSE, SEIZURES, TREMORS, AGNOSIA

  1. Explain the comprehensive assessment for a client suffering from Alzheimer’s disease.

    • A comprehensive assessment includes:

      • History: Gathering information on onset, duration, progression of symptoms, functional status, and behavioral changes.

      • Physical Assessment: Evaluating cognitive functions (attention, concentration, judgment, perception, learning memory, and communication).

      • Psychosocial Assessment: Obtaining information about social and emotional well-being.

      • Laboratory and Imaging Assessment: Utilizing CT scans, MRIs, and genetic testing. Autopsy (brain tissue examination) is the only definitive diagnosis.

  2. Interpret the expected assessment findings for a client suffering from Alzheimer’s disease to determine actual and potential consequences.

    • Expected findings progress from mild disorientation and handling daily activities in Stage I, to significant cognitive impairments, dependency in ADLs, visuospatial deficits, speech/language difficulties, incontinence, wandering, and psychotic behaviors in Stage II. In Stage III, findings include total dependency, loss of mobility and verbal communication, seizures, tremors, and agnosia. These findings lead to actual consequences like decreased memory and cognition, and potential consequences such as injury, falls, and elder abuse.

  3. Identify client goals and determine expected outcomes for a client suffering from Alzheimer’s disease.

    • Client goals and expected outcomes focus on:

      • Maintenance of cognitive functions and memory (to the extent possible).

      • Prevention of injuries/falls.

      • Prevention of elder abuse.

      • Management of caregiver stress.

  4. Describe nursing and collaborative interventions required to treat and monitor a client suffering from Alzheimer’s disease.

    • Cognitive and Nonpharmacologic Interventions: Cognitive stimulation (puzzles, memory games), environmental structuring for safety and navigation, orientation/validation therapy, self-management promotion, continence promotion, and communication support.

    • Care Coordination and Transition Management: Home care management plans, respite care options for caregivers, and education for families on behavior management, drug therapy, and maintaining mobility.

  5. Identify pharmacological therapy used to treat Alzheimer’s disease and associated considerations.

    • While no drugs slow the progression, some may improve symptoms:

      • Cholinesterase Inhibitors: Donepezil (Aricept), Galantamine (Razadyne), Rivastigmine (Exelon).

      • Memantine (Namenda): NMDA receptor antagonist.

      • Vitamin E: Used for cognitive health.

      • SSRIs for depression: Paroxetine (Paxil), Sertraline (Zoloft).

      • Psychotropic Drugs: (for agitation, aggression, psychosis) Aripiprazole (Abilify), Clozapine (Clozaril), Haloperidol (Haldol), among others.

  6. Identify family and caregiver challenges and education priorities.

    • Challenges include managing symptoms of a progressive disease, significant care requirements, and caregiver stress. Education priorities include instructing families on behavior management strategies, understanding and administering drug therapy, and supporting the patient in maintaining mobility for as long as possible. Managing caregiver stress is crucial to mitigate the risk of elder abuse.

Parkinson’s Disease Overview

  • Definition: Parkinson’s Disease (PD) is a progressive neurodegenerative disorder primarily affecting dopamine-producing neurons in a specific area of the brain called the substantia nigra.

  • Key Characteristics: It is characterized by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability, as well as several non-motor symptoms.

  • Cure Status: Currently, there is no cure for Parkinson's Disease; treatments focus on managing symptoms.

Pathophysiology of Parkinson’s Disease

  • Neuronal Loss: Degeneration and loss of dopaminergic neurons in the substantia nigra in the midbrain.

  • Neurotransmitter Imbalance: Leads to a deficiency of dopamine, crucial for coordinating movement.

  • Lewy Bodies: Presence of abnormal protein aggregates called Lewy bodies, primarily composed of alpha-synuclein, within neurons.

Clinical Manifestations of Parkinson’s Disease

Motor Symptoms (TRAP)

  • Tremor: Often beginning in a limb, especially at rest (resting tremor), typically a "pill-rolling" motion of the thumb and forefinger.

  • Rigidity: Stiffness of the limbs and trunk; can be "cogwheel rigidity" (jerky movements when the limb is moved).

  • Akinesia/Bradykinesia: Slowness of movement (bradykinesia) or absence of movement (akinesia). This can make initiating movement difficult and lead to a shuffling gait, difficulty with fine motor tasks, and reduced facial expressions (mask-like face).

  • Postural Instability: Impaired balance and coordination, increasing the risk of falls.

Non-Motor Symptoms

  • Cognitive Changes: Mild cognitive impairment eventually progressing to dementia in later stages.

  • Mood Disorders: Depression, anxiety, apathy.

  • Sleep Problems: Insomnia, REM sleep behavior disorder.

  • Autonomic Dysfunction: Constipation, orthostatic hypotension, urinary problems.

  • Olfactory Dysfunction: Reduced sense of smell.

Management of Parkinson’s Disease

  • Goal: Manage symptoms and improve quality of life, as there is no cure.

  • Pharmacological Therapy:

    • Levodopa (L-DOPA): Most effective medication, converted to dopamine in the brain. Often combined with carbidopa (Sinemet) to reduce side effects.

    • Dopamine Agonists: Mimic the effects of dopamine in the brain (e.g., Pramipexole, Ropinirole).

    • MAO-B Inhibitors: Prevent the breakdown of dopamine (e.g., Selegiline, Rasagiline).

    • COMT Inhibitors: Extend the effect of Levodopa (e.g., Entacapone).

  • Surgical Interventions:

    • Deep Brain Stimulation (DBS): Implantation of electrodes in specific brain areas, connected to a pulse generator, to regulate abnormal brain activity. Generally for advanced PD when medication effects fluctuate.

  • Supportive Therapies: Physical therapy, occupational therapy, speech therapy, nutritional counseling.

  • Health Promotion: Regular exercise, balanced diet, mental stimulation.